Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorprothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorprothixene SCHEMBL94235 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL30383335 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL94236 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL24133 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29357955 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL455759 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL455758 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29857011 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL3491182 | 0.92 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29462906 | 0.90 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410474-B2 | Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient | NORTHWESTERN UNIVERSITY (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2025-07-31 | — | — | US | disclosed |
| US-20250101104-A1 | BISPECIFIC MOLECULE WITH TUNABLE AFFINITY TO A TARGETED ANTIGEN | MABSWITCH INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240350483-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2024-10-24 | — | — | US | disclosed |
| US-20240325437-A1 | METHODS AND COMPOSITIONS FOR USE IN IMPROVING ADAPTIVE IMMUNITY IN THE ELDERLY POPULATION | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-10-03 | — | — | US | disclosed |
| US-20230386637-A1 | Polymorphisms for Predicting Treatment Response to Antipsychotic Drugs and Identifying New Drug Targets | NORTHWESTERN UNIVERSITY | 2023-11-30 | — | — | US | disclosed |
| US-20220177970-A1 | METHODS, KITS, AND DEVICES FOR DIAGNOSING, PROGNOSING, AND TREATING PSYCHIATRIC DISORDERS IN A PATIENT | NORTHWESTERN UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CAVION, INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350483-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | SLC6A4, SLC6A2, SLC6A3 | DRD2 18/4885DRD3 74/4885HTR2A 47/4885 |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CACNA1G, CACNA1I, CACNA1H | DRD2 324/4885DRD3 436/4885HTR2A 130/4885 |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | SLC6A4, SLC6A2, SLC6A3 | DRD2 18/4885DRD3 74/4885HTR2A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.